- Home
- Cardiology
- Inclisiran: A Long-Acting siRNA Therapy for LDL-C Reduction
1mo2 min read
Medical Article
Introduction: Hyperlipidemia remains a major contributor to atherosclerotic cardiovascular disease (ASCVD) despite widespread use of statins and other lipid-lowering therapies (1). Many patients fail to achieve recommended low-density lipoprotein cholesterol (LDL-C) targets with conventional treatment alone, highlighting the need for additional the

Inclisiran: A Long-Acting siRNA Therapy for LDL-C Reduction
21 Reached1 Comments
Similar Content

Characteristics, Outcomes and Predictors of Long-Term Mortality for Patients Hospitalized for Acute Heart Failure
150 Reached

ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes

Catheter Ablation for Atrial Fibrillation with HF
691 Reached

Male Complaining of Bilateral Knee Pain and Gait Disturbance
840 Reached5 Comments1 Likes

Patient with History of Atrial Fibrillation
519 Reached3 Likes
